Anticancer mechanism and application of curcumin analog EF24

doi:10.3760/cma.j.issn.1673-422X.2018.03.010

Abstract

Abstract: Curcumin is a polyphenol pigment product from the rhizome of curcumin longa. It is associated with numerous therapeutic benefits, including antioxidant, antiinflammatory and anticancer activities. Research shows that EF24 is a curcumin analog that can induce tumor cell apoptosis, arrest cell cycle, inhibit cell invasion and metastasis and has synergistic effect of combined antitumor agents. EF24 has improved anticancer activity and bioavailability against various cancer cell lines over curcumin without increased toxicity. EF24 would have great potential to be used as a useful therapeutic agent for the treatment of various types of cancer.

Key words: Antineoplastic agents, Curcumin, EF24

Ling Xiaofei, Xu Ke, Shao Hua, Wang Cuijuan. Anticancer mechanism and application of curcumin analog EF24[J]. Journal of International Oncology, 2018, 45(3): 172-175.

References

［1］ Wu JZ, Wu SB, Shi LY, et al. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anticancer agents for lung cancer［J］. Eur J Med Chem, 2017, 125: 1321-1331. DOI: 10.1016/j.ejmech.2016.10.027. ［2］韩金荣, 张林西. 姜黄素抗肿瘤作用机制［J］. 国际肿瘤学杂志, 2013, 40(11): 823-826. DOI: 10.3760/cma.j.issn.1673-422X.2013.11.007. ［3］ Bisht S, Schlesinger M, Rupp A, et al. A liposomal formulation of the synthetic curcumin analog EF24 (LipoEF24) inhibits pancreatic cancer progression: towards future combination therapies［J］. J Nanobiotechnology, 2016, 14(1): 57. DOI: 10.1186/s12951-016-0209-6. ［4］ He G, Feng C, Vinothkumar R, et al. Curcumin analog EF24 induces apoptosis via ROSdependent mitochondrial dysfunction in human colorectal cancer cells［J］. Cancer Chemother Pharmacol, 2016, 78(6): 1151-1161. DOI: 10.1007/s00280-016-3172-x. ［5］ Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NFκB and miRNA-21, and has potent anticancer activity in vitro and in vivo［J］. PLoS One, 2013, 8(8): e71130. DOI: 10.1371/journal.pone.0071130. ［6］ Kasinski AL, Du Y, Thomas SL, et al. Inhibition of IkappaB kinasenuclear factorkappaB signaling pathway by 3,5bis(2flurobenzylidene)piperidin4one (EF24), a novel monoketone analog of curcumin［J］. Mol Pharmacol, 2008, 74(3): 654661. DOI: 10.1124/mol.108.046201. ［7］ Yin DL, Liang YJ, Zheng TS, et al. EF24 inhibits tumor growth and metastasis via suppressing NFkappaB dependent pathways in human cholangiocarcinoma［J］. Sci Rep, 2016, 6: 32167. DOI: 10.1038/srep32167. ［8］ Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS［J］. Nature, 2011, 475(7355): 231-234. DOI: 10.1038/nature10167. ［9］ Peng Z, Xia Y, Chen W, et al. EF24 induces ROSmediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells［J］. Oncotarget, 2016, 7(14): 18050-18064. ［10］ Thomas SL, Zhong D, Zhou W, et al. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF1［J］. Cell Cycle, 2008, 7(15): 2409-2417. DOI: 10.4161/cc.6410. ［11］ Fragkos M, Ganier O, Coulombe P, et al. DNA replication origin activation in space and time［J］. Nat Rev Mol Cell Biol, 2015, 16(6): 360-374. DOI: 10.1038/nrm4002. ［12］ Liu HT, Liang YJ, Wang LL, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog［J］. PLoS One, 2012, 7(10): e48075. DOI: 10.1371/journal.pone.0048075. ［13］ Meek DW. Regulation of the p53 response and its relationship to cancer［J］. Biochem J, 2015, 469(3): 325-346. DOI: 10.1042/BJ20150517. ［14］ Subramaniam D, May R, Sureban SM, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity［J］. Cancer Res, 2008, 68(6): 1962-1969. DOI: 10.1158/00085472.CAN-07-6011. ［15］ Dvorak HF. Tumors: wounds that do not healredux［J］. Cancer Immunol Res, 2015, 3(1): 1-11. DOI: 10.1158/23266066.CIR-14-0209. ［16］李纯苓, 王朝霞, 王恒孝. HIF1α、PDGF与VEGF、VEGFR在乳腺癌发病中的表达及意义［J］. 国际肿瘤学杂志, 2014, 41(11): 858-865. DOI: 10.3760/cma.j.issn.1673-422X.2014.11.018. ［17］ Liu W, Kovacevic Z, Peng Z, et al. The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets［J］. Oncotarget, 2015, 6(34): 35522-35541. DOI: 10.18632/oncotarget.5849. ［18］ Zhao R, Tin L, Zhang Y, et al. EF24 suppresses invasion and migration of hepatocellular carcinoma cells in vitro via inhibiting the phosphorylation of Src［J］. Biomed Res Int, 2016, 2016: 8569684. DOI: 10.1155/2016/8569684. ［19］曹纯, 马晓洁, 谭榜宪. 缺氧诱导因子-1α与上皮间质转化［J］. 国际肿瘤学杂志, 2014, 41(6): 415-418. DOI: 10.3760/cma.j.issn.1673-422X.2014.06.005. ［20］ Zhang P, Bai H, Liu G, et al. MicroRNA33b, upregulated by EF24, a curcumin analog, suppresses the epithelialtomesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2［J］. Toxicol Lett, 2015, 234(3): 151161. DOI: 10.1016/j.toxlet.2015.02.018. ［21］ Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF24 targeting glucose transporter 1mediated metabolism and metastasis in ovarian cancer cells［J］. Cancer Sci, 2013, 104(12): 1690-1696. DOI: 10.1111/cas.12293. ［22］ Liang Y, Yin D, Hou L, et al. Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma［J］. PLoS One, 2011, 6(8): e23908. DOI: 10.1371/journal.pone.0023908. ［23］ Chen W, Zou P, Zhao Z, et al. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer［J］. Redox Biol, 2016, 10: 78-89. DOI: 10.1016/j.redox.2016.09.006. ［24］ Onen HI, Yilmaz A, Alp E, et al. EF24 and RAD001 potentiates the anticancer effect of platinumbased agents in human malignant pleural mesothelioma (MSTO211H) cells and protects nonmalignant mesothelial (MET5A) cells［J］. Hum Exp Toxicol, 2015, 34(2): 117-126. DOI: 10.1177/0960327114542965. ［25］ Liang Y, Zheng T, Song R, et al. Hypoxiamediated sorafenib resistance can be overcome by EF24 through Von HippelLindau tumor suppressordependent HIF-1α inhibition in hepatocellular carcinoma［J］. Hepatology, 2013, 57(5): 1847-1857. DOI: 10.1002/hep.26224. ［26］ Aravindan S, Natarajan M, Awasthi V, et al. Novel synthetic monoketone transmute radiationtriggered NFκBdependent TNFα crosssignaling feedback maintained NFκB and favors neuroblastoma regression［J］. PLoS One, 2013, 8(8): e72464. DOI: 10.1371/journal.pone.0072464.

[1]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[3]	Wang Shuang, Tang Yunyun, Yue Qi. New progress in antitumor research of non-psychoactive cannabidiol [J]. Journal of International Oncology, 2020, 47(10): 619-623.
[4]	Yi Lin, Qiu Shi. Anti-tumor effect and mechanisms of shikonin on gliomas [J]. Journal of International Oncology, 2019, 46(8): 489-491.
[5]	Liang Jing1,3, Han Sha2, Yao Jing3, Kong Qingsheng2. Effect of histone deacetylase and its inhibitor on tumor [J]. Journal of International Oncology, 2019, 46(4): 235-238.
[6]	Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong. Molecular targeted therapy for advanced kidney cancer [J]. Journal of International Oncology, 2019, 46(12): 705-710.
[7]	Wang Gang, Wang Huangzhen, Xue Ting. Effect of oxaliplatin induced autophagy on drug resistance of SGC7901 gastric cancer cells [J]. Journal of International Oncology, 2018, 45(8): 513-518.
[8]	Chen Gang, Zhuang Fangcheng. High mobility group box 1 and its role in cervical cancer [J]. Journal of International Oncology, 2017, 44(3): 235-238.
[9]	Liu Lan, Zhang Zhimin, Peng Wenmiao, Fu Hongxing, Rao Zhiguo. Reversal of Pglycoproteinmediated multidrug resistance mechanism by curcumin [J]. Journal of International Oncology, 2017, 44(10): 758-761.
[10]	Dong Yi, Wei Yuehua, Hu Weiguo, Song Qibin. Therapy for non-small cell lung cancer patients with solitary bone metastases [J]. Journal of International Oncology, 2017, 44(1): 60-62.
[11]	Cai Xiaojun, Han Lijuan, Wei Ping. Curcumin downregulation of MGMT expression to enhance the chemosensitivity of temozolomide on maligant glioblastoma [J]. Journal of International Oncology, 2016, 43(8): 565-569.
[12]	DU Ji-Hui, ZHANG Hou-De, WEI Jing, WANG Lei, SUN Ting-Ji. Correlation of peroxisome pathway reactive oxygen species oxidative stress gene and its correlation with the antitumor sensitivity of artesunate against pancreatic cancer [J]. Journal of International Oncology, 2016, 43(7): 503-507.
[13]	Tian Ruonan,Sun Jianjing, Zhang Linxi. Mechanism of curcumin resisting esophageal cancer [J]. Journal of International Oncology, 2016, 43(5): 379-381.
[14]	LIU Dong-Ju, ZHAO Qiu-Sheng, YAO Yu. Effects of curcumin combined with cisplatin on growth and lymphatic metastasis of cervical cancer xenografts in nude mice [J]. Journal of International Oncology, 2016, 43(4): 241-245.
[15]	ZHANG Wen-Dian, XU Zu-Min, YU Zhong-Hua. Antitumor mechanism of gambogic acid [J]. Journal of International Oncology, 2016, 43(4): 293-295.